The results revealed that once-daily dosing of osimertinib only delayed in vivo tumor development in the HCC827, H3255, and H1975 xenografts (Fig. 7a-f, Supplementary Figure 5A-C) which harbored EGFR activating mutation. The gene discussed is EGFR; the disease is neoplasm.